BlackRock, Inc. Amends Schedule 13G for Tonix Pharmaceuticals Holding Corp.

BlackRock, Inc. has filed an amendment to its Schedule 13G for Tonix Pharmaceuticals Holding Corp., reporting a decrease in its ownership. As of September 30, 2025, BlackRock beneficially owns 680,036 shares of common stock, representing 7.8% of the total outstanding shares. This marks a significant decrease from its previous holdings, with a value change of -$6,551,753,568.36 and a shares change of -5,642,421. The filing indicates that BlackRock acquired and holds these securities in the ordinary course of business and not for the purpose of influencing control of the issuer. The amendment includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification.